Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29


Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.

Liang B, Ngwuta JO, Surman S, Kabatova B, Liu X, Lingemann M, Liu X, Yang L, Herbert R, Swerczek J, Chen M, Moin SM, Kumar A, McLellan JS, Kwong PD, Graham BS, Collins PL, Munir S.

J Virol. 2017 Jul 12;91(15). pii: e00189-17. doi: 10.1128/JVI.00189-17. Print 2017 Aug 1.


Efficient and Robust Paramyxoviridae Reverse Genetics Systems.

Beaty SM, Park A, Won ST, Hong P, Lyons M, Vigant F, Freiberg AN, tenOever BR, Duprex WP, Lee B.

mSphere. 2017 Mar 29;2(2). pii: e00376-16. doi: 10.1128/mSphere.00376-16. eCollection 2017 Mar-Apr.


Parainfluenza Virus 3 Blocks Antiviral Mediators Downstream of the Interferon Lambda Receptor by Modulating Stat1 Phosphorylation.

Eberle KC, McGill JL, Reinhardt TA, Sacco RE.

J Virol. 2015 Dec 30;90(6):2948-58. doi: 10.1128/JVI.02502-15.


The M, F and HN genes of genotype VIId Newcastle disease virus are associated with the severe pathological changes in the spleen of chickens.

Kai Y, Hu Z, Xu H, Hu S, Zhu J, Hu J, Wang X, Liu X, Liu X.

Virol J. 2015 Sep 4;12:133. doi: 10.1186/s12985-015-0366-5.


Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.

Liang B, Surman S, Amaro-Carambot E, Kabatova B, Mackow N, Lingemann M, Yang L, McLellan JS, Graham BS, Kwong PD, Schaap-Nutt A, Collins PL, Munir S.

J Virol. 2015 Sep;89(18):9499-510. doi: 10.1128/JVI.01373-15. Epub 2015 Jul 8.


Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics.

Pfaller CK, Cattaneo R, Schnell MJ.

Virology. 2015 May;479-480:331-44. doi: 10.1016/j.virol.2015.01.029. Epub 2015 Feb 18. Review.


Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection.

Liang B, Munir S, Amaro-Carambot E, Surman S, Mackow N, Yang L, Buchholz UJ, Collins PL, Schaap-Nutt A.

J Virol. 2014 Apr;88(8):4237-50. doi: 10.1128/JVI.03481-13. Epub 2014 Jan 29.


Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children.

Englund JA, Karron RA, Cunningham CK, Larussa P, Melvin A, Yogev R, Handelsman E, Siberry GK, Thumar B, Schappell E, Bull CV, Chu HY, Schaap-Nutt A, Buchholz U, Collins PL, Schmidt AC; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1096 Study Group.

Vaccine. 2013 Nov 19;31(48):5706-12. doi: 10.1016/j.vaccine.2013.09.046. Epub 2013 Oct 5.


Influence of antigen insertion site and vector dose on immunogenicity and protective capacity in Sendai virus-based human parainfluenza virus type 3 vaccines.

Mason JN, Elbahesh H, Russell CJ.

J Virol. 2013 May;87(10):5959-69. doi: 10.1128/JVI.00227-13. Epub 2013 Mar 20.


Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children.

Karron RA, Thumar B, Schappell E, Surman S, Murphy BR, Collins PL, Schmidt AC.

Vaccine. 2012 Jun 6;30(26):3975-81. doi: 10.1016/j.vaccine.2011.12.022. Epub 2011 Dec 14.


Progress in the development of human parainfluenza virus vaccines.

Schmidt AC, Schaap-Nutt A, Bartlett EJ, Schomacker H, Boonyaratanakornkit J, Karron RA, Collins PL.

Expert Rev Respir Med. 2011 Aug;5(4):515-26. doi: 10.1586/ers.11.32. Review.


Progress in respiratory virus vaccine development.

Schmidt AC.

Semin Respir Crit Care Med. 2011 Aug;32(4):527-40. doi: 10.1055/s-0031-1283289. Epub 2011 Aug 19. Review.


Roles of the fusion and hemagglutinin-neuraminidase proteins in replication, tropism, and pathogenicity of avian paramyxoviruses.

Kim SH, Subbiah M, Samuel AS, Collins PL, Samal SK.

J Virol. 2011 Sep;85(17):8582-96. doi: 10.1128/JVI.00652-11. Epub 2011 Jun 15.


Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.

Jones B, Zhan X, Mishin V, Slobod KS, Surman S, Russell CJ, Portner A, Hurwitz JL.

Vaccine. 2009 Mar 13;27(12):1848-57. doi: 10.1016/j.vaccine.2009.01.041. Epub 2009 Feb 4.


Nonsegmented negative-strand viruses as vaccine vectors.

Bukreyev A, Skiadopoulos MH, Murphy BR, Collins PL.

J Virol. 2006 Nov;80(21):10293-306. Review. No abstract available.


Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.

Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, Collins PL.

Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9. Epub 2004 Jun 21.


The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness.

Skiadopoulos MH, Biacchesi S, Buchholz UJ, Riggs JM, Surman SR, Amaro-Carambot E, McAuliffe JM, Elkins WR, St Claire M, Collins PL, Murphy BR.

J Virol. 2004 Jul;78(13):6927-37.


Parainfluenza viruses.

Henrickson KJ.

Clin Microbiol Rev. 2003 Apr;16(2):242-64. Review.

Supplemental Content

Support Center